351 related articles for article (PubMed ID: 3493209)
1. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
Hinuma S; Naruo K; Ootsu K; Houkan T; Shiho O; Tsukamoto K
Immunology; 1987 Feb; 60(2):173-9. PubMed ID: 3493209
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
[TBL] [Abstract][Full Text] [Related]
5. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
Yoshioka T; Sato S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice.
Gorelik E
Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083
[TBL] [Abstract][Full Text] [Related]
7. Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice.
Gately MK; Anderson TD; Hayes TJ
J Immunol; 1988 Jul; 141(1):189-200. PubMed ID: 3259967
[TBL] [Abstract][Full Text] [Related]
8. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
10. [Role of asialo GM 1 positive cells in the control of metastatic spread of tumor cells in mice].
Shibuya M; Saijo N; Ozaki A; Beppu Y; Shimizu E; Takizawa T; Hoshi A
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1781-6. PubMed ID: 6882003
[TBL] [Abstract][Full Text] [Related]
11. Asialo-GM1-positive T killer cells are generated in F1 mice injected with parental spleen cells.
Knobloch C; Dennert G
J Immunol; 1988 Feb; 140(3):744-9. PubMed ID: 2448375
[TBL] [Abstract][Full Text] [Related]
12. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.
Anderson TD; Hayes TJ; Gately MK; Bontempo JM; Stern LL; Truitt GA
Lab Invest; 1988 Nov; 59(5):598-612. PubMed ID: 3263543
[TBL] [Abstract][Full Text] [Related]
14. Treatment of mice with anti-asialo-GM1 antibody or poly-I:C: effects on metastasis dissociable from modulation of macrophage antitumor activity.
Riser BL; Laybourn KA; Varani J
Nat Immun Cell Growth Regul; 1988; 7(5-6):305-15. PubMed ID: 3221908
[TBL] [Abstract][Full Text] [Related]
15. The suppressive effect of anti-asialo GM1 antibody on low-dose streptozotocin-induced diabetes in CD-1 mice.
Maruyama T; Watanabe K; Yanagawa T; Kasatani T; Kasuga A; Shimada A; Takei I; Suzuki Y; Kataoka K; Saruta T
Diabetes Res; 1991 Apr; 16(4):171-5. PubMed ID: 1802483
[TBL] [Abstract][Full Text] [Related]
16. Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2-associated control: different behavior of H-2+ and H-2- cells in metastatic processes.
Kawano Y; Taniguchi K; Toshitani A; Nomoto K
J Immunol; 1986 Jun; 136(12):4729-34. PubMed ID: 3711664
[TBL] [Abstract][Full Text] [Related]
17. In vivo requirement for asialo GM1 and Thy1 positive leukocytes for antitumor effect of rIL-2 +/- rIFN-gamma.
Silagi S; Dutkowski R; Schaefer A
Anticancer Res; 1988; 8(6):1265-9. PubMed ID: 2905882
[TBL] [Abstract][Full Text] [Related]
18. Purification and target cell range of in vivo elicited blast natural killer cells.
Biron CA; Pedersen KF; Welsh RM
J Immunol; 1986 Jul; 137(2):463-71. PubMed ID: 3722814
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
